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Jawitz et al Cardiothoracic Transplantationmaking and to maximize efficiency within the available
donor pool. This will help optimize the use of donor organs,
an extremely important, yet scarce, resource. In doing so,
waiting times could be shortened and overall outcomes
could be improved. In addition, because ABO blood type
O donor grafts are associated with decreased survival after
transplant, current organ allocation policies should be re-
viewed, particularly those pertaining to ABO blood type
B heart transplant recipients.
We thank Ms. Elsa Su, MS (Statistics), for helping in the prep-
aration of the manuscript and the Yale School of Medicine Office
of Student Research for support.T
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Dr Nader Moazami (Cleveland, Ohio). Well, let me start by
congratulating you on your presentation. Many of us who were
at your stage in our careers have not had the opportunity to present
in such a prestigious forum, and I am hopeful that this bodes well
for your future in academic surgery. I will start with a few general
comments and then at the end ask my questions.
I think the topic and title of this talk are interesting. For many
transplant clinicians, the issue of ABO-compatible transplantation
seems to have been put to rest, particularly in the era of continued
organ shortage. In fact, the current trend in the literature is largely
focused on a completely opposite and different strategy, that is,
ABO-incompatible transplantation. This strategy has been widely
applied in the renal world and has led to an increase in the number
of living-related kidney transplantations. A similar strategy has
been successfully applied in the neonatal and pediatric heart trans-
plant population for whom the availability of organs in a timely
fashion is limited.
Now, most of us think of ABO as antigens expressed on the sur-
face of red blood cells, but in fact they are widely expressed on
endothelial cells, including those of the heart. The specter of anti-
body-mediated hyperacute rejection is what has made ABO-
incompatible heart transplantation a hurdle in adults and, in the
current era of LVADs, of much less interest. So the question is,
where does ABO-compatible heart transplantation fit in our overall
practice and how important is this in terms of graft and patient sur-
vival, a question that you have attempted to analyze in your presen-
tation today.
I am going to draw 3 broad conclusions from your presentation
and follow thosewith questions, and I will wait for your answer for
each one.
As you know, graft failure is multifactorial and depends
on many donor and recipient variables, some of which you have
accounted for in your analysis, particularly those markers that
identify sicker patients. I am not sure if in your analysis other
well-known variables, such as pulmonary hypertension, recipient
and donor age, and ischemic times, have been accounted for.
Did you look at any of these factors for graft failure in your multi-
variable model?
Mr Jawitz. First of all, thank you, Dr Moazami, for your enthu-
siastic support and criticism. As a medical student planning to pur-
sue a career in surgery, it really means a lot to me.
To answer your question, we were able to look at some of those
variables in the database. Unfortunately, we were limited by the
variables that were coded in the UNOS database, and in some in-
stances there was a significant amount of data missing. In our
multivariate analysis, however, we actually did show that total bili-
rubin time, ethnicity, and a number of other variables were actually
independently associated with poorer outcomes. Pulmonary hy-
pertension was included in our cause of death analysis, but not
in our pretransplant univariate analysis of recipient baseline
characteristics.diovascular Surgery c Volume 146, Number 5 1245
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XDrMoazami. That brings me to the second conclusion that you
drew, and that is that ABO-compatible heart transplantation is
an acceptable strategy and unlikely to impact short- or long-term
survival. In fact, the International Society of Heart and Lung
Transplantation, which is a large registry of all transplant recipi-
ents, on an annual basis evaluates all transplant-related data. Inter-
estingly, occasionally a small improved survival difference has
been seen between ABO-identical and ABO-compatible donors.
However, this generally has been negligible and largely accounted
for by many other markers of immunogenicity, namely, the degree
of HLA mismatching. This brings me to the next question for you.
In looking at short- and long-term results, the immunogenicity
of MHC antigens and also presence of donor-specific antibodies
play a large role in graft viability. In your analysis, were any of
these factors, specifically HLA matching, panel-reactive antibody
levels, or cross match results, available and accounted for?
Mr Jawitz. Thank you very much. That is an excellent ques-
tion. Yes, it is true that HLA matching is extremely important in
long-term graft outcomes. I believe, in the last 10 years, research
conducted by Opelz and colleagues, the collaborative transplant
study, showed that 2 HLA-A, HLA-B, or HLA-DR mismatches
were actually associated with 25% increased graft failure
compared to 0 or 1 mismatch within 3 years of transplant. In terms
of our study, we really wanted to keep it simple and specifically
focus on ABO blood types, namely, ABO-compatible versus
ABO-identical matches. In addition, a recently published article
specifically looking at renal transplantation showed no correlation
between HLA matching and ABO blood type matching.
I do agree that HLA typewould be interesting to look at and see,
specifically, how differences in HLA blood type between donors
and recipients have impacted these data.
Dr Moazami. Finally, I caution against one of your conclu-
sions, which is regarding decreased survival of blood type O do-
nors for, specifically, blood type B recipients. The UNOS
organization mandate is based on 2 major premises: (1) the equity
in organ allocation and (2) in maximizing the survival benefit for
recipients that are at the highest risk of dying. The policy of allo-
cating O donor hearts to type O recipients first and then type B is a
reflection of this policy. Type O recipients can only receive organs
from type O and, hence, typically have longer wait times on the
list. Similarly, type B in the United States comprises only about
10% of the population and, hence, they are at a disadvantage
compared to type A blood that comprises about 40% of the
population.
So, with the Kaplan-Meier curve that you showed at the end in
terms of the blood donor O to B recipients, were any of these risk
adjusted, and is it possible that if we correct for some of the factors
that I mentioned previously related to immunogenicity that these
small differences in survival will disappear?
Mr Jawitz. Yes, that is a good question. We actually looked at
primary graft failure as an outcome between donor type O hearts1246 The Journal of Thoracic and Cardiovascular Surgoing to type B individuals and type B hearts going to type B re-
cipients, and we actually found out that compatible matches, that
is, type O hearts going to type B recipients, were actually associ-
ated with increased rates of primary graft failure.
As for the current OPTN policy and organ allocation scheme,
you are right, the reason that blood type B recipients preferentially
receive type O organs is because of the short supply of type B
hearts in this country.When approaching a potential change in pol-
icy, it would be important to ensure that that any decrease in donor
heart availability for type B recipients would be more than made
up for by significantly improved posttransplant outcomes. More
analysis is certainly needed before we would feel comfortable rec-
ommending such a policy.
Dr Moazami. Thank you.
Dr DavidMcGiffin (Birmingham, Ala). I just want to follow on
from that point. Youmentioned in your manuscript and in your talk
about the poorer survival of blood O to B. You have demonstrated
that there are no immunological consequences of that, but O to B is
most likely a surrogate for sicker donors and sicker recipients. On
that basis, though, howwould you change the allocation system for
what is probably an immutable problem?
Mr Jawitz. That is a good question. As Dr Moazami pointed
out, the reason why blood type B recipients are receiving blood
type O donor hearts is because of the comparative shortage of
type B donor hearts in this country. To really change the current
allocation scheme, we would have to take into account the poten-
tial of actually harming type B individuals by changing the policy.
I do not think there is a really great answer to how to specifically
change the policy at this point and I certainly believe that more
research is warranted.
The senior author on this paper actually believes that changing
the pretransplant management of type B patients, that is instead of
rushing to transplant themwith a type O donor heart, perhaps using
an LVAD as a bridge to transplant as you wait for an identical type
B donor graft, may be a method of mitigating this problem.
Dr Pieter Kappetein (Rotterdam, The Netherlands). You
showed that there is a significant difference between the different
groups, especially for the blood type O patients. Of course, this is a
large group of patients. For example, in the A-B group, you have
few patients, and might that not be a type II error that maybe there
might also be a difference there because you do not have enough
patients that you do not see the difference?
Mr Jawitz.You are absolutely right. Wewere limited by the data-
base that we had and in several instances due to incomplete data and a
lack of certain variables, we were unable to answer all of our
questions.
Dr Kappetein. And, of course, therefore, in a group where you
have enough patients you can identify easier a difference and while
in the groups that are smaller there might be a difference as well
but it might be more difficult to identify.
Mr Jawitz. Yes, you are correct.gery c November 2013
